エピトランスクリプトミクスの不調は,アルテミシンの作用のメカニズムを支えている
bioRxiv : the preprint server for biology
|September 5, 2025
まとめ
アルテミシニン
科学分野:
- マラリアと寄生虫学
- 分子生物学 と 遺伝学
- 薬の発見と開発
背景:
- アルテミシニンは重要な抗マラリア薬ですが,その正確な作用メカニズムは不明です.
- アルテミシニン耐性マラリア寄生虫の出現は 改善された治療法を開発するために 寄生虫の機能のより深い理解を 求めています
- 新しい薬の標的を特定することは,マラリアと闘い,耐性を克服するために極めて重要です.
研究 の 目的:
- アルテミシニンの抗マラリア作用の分子メカニズムを解明する.
- 寄生虫の翻訳機構とtRNAの改変に対するアルテミシニン治療の影響を調査する.
- 新薬開発のための寄生虫の表写体内の潜在的な脆弱性を特定する.
主な方法:
- 比較トランスクリプトミクス (RNA配列解析) とアルテミシニンで処理されたP.ファルシパラムを分析するプロテミクス
- 液体染色学結合質量スペクトロメトリー (LC-MS) で,tRNAの修正されたリボヌクレオシドを定量化する.
- コドン利用とtRNA改変経路に焦点を当てた遺伝子発現変化の分析
主要な成果:
- アルテミシニン治療は,異なった翻訳遺伝子のコドン利用パターンの有意な変化を誘発した.
- 37位にある特定のtRNA変異であるN6 - トレオニルカルバモイラデノシン (t6A) は,アルテミシニンのストレス下では低変異であることが判明した.
- アルテミシニン治療の後,生物合成に不可欠なPfSua5のダウンレギュレーションが観察されました.
結論:
- アルテミシニンの作用は,tRNAの改変経路を妨害し,特にt 6 Aに影響を与える.
- tRNAエピトランスクリプトームは,P. falciparum*における潜在的な治療的脆弱性を表しています.
- これらの発見は 次世代の抗マラリア薬の開発に 新たな道を開きます
さらに関連する動画
10:22Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
9.0K
08:22IR-TEx: An Open Source Data Integration Tool for Big Data Transcriptomics Designed for the Malaria Vector Anopheles gambiae
Published on: January 15, 2020
6.2K
関連する概念動画
MicroRNAs
21.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
RNA Stability
31.6K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
31.6K
Riboswitches
8.0K
Riboswitches are non-coding mRNA domains that regulate the transcription and translation of downstream genes without the help of proteins. Riboswitches bind directly to a metabolite and can form unique stem-loop or hairpin structures in response to the amount of the metabolite present. They have two distinct regions – a metabolite-binding aptamer and an expression platform.
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
8.0K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
